. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Ann Surg Oncol. 2017 May 30;24(9):2556–2562. doi: 10.1245/s10434-017-5898-z

Table 4.

Rates of breast and axillary downstaging by grouped pathologic features

	Breast		Axilla
Receptor/Grade/Differentiation	BCS Candidate After NAC (n=239)^*	p-value	Nodal pCR (n=301)^**	p-value
PR+/High grade or poorly differentiated	44% (37/85)	0.005	14% (16/117)	<0.0001
PR+/Non-high grade and not poorly differentiated	29% (24/82)		8% (8/98)
PR−/High grade or poorly differentiated	62% (26/42)		35% (17/48)
PR−/Non-high grade and not poorly differentiated	35% (8/23)		0% (0/29)

Analysis excludes 3 patients with unknown grade and differentiation and 4 ER−PR+ patients

^**

Analysis excludes 5 patients with unknown grade and differentiation and 4 ER−PR+ patients

BCS, breast-conserving surgery; NAC, neoadjuvant chemotherapy; PR, progesterone receptor